Charles River Laboratories International Inc. (CRL) Stock

Valuation data is not available for this stock.

With a beta of 1.48, Charles River Laboratories International Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 2.31 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Charles River Laboratories International Inc. achieves a profit margin of -0.49%, meaning it retains $-0.49 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 13.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -0.67% and ROA at 4.27%, the company achieves moderate returns on invested capital.

Charles River Laboratories International Inc.'s revenue declined by 2.70% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 61.50% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry averages for proper context.

Charles River Laboratories International Inc. has a market capitalization of $7.37B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 49.12M shares outstanding, the company's ownership is relatively concentrated. As a participant in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry, it competes with other firms in this sector.

Charles River Laboratories International Inc.'s book value per share is $65.04, while the current stock price is $176.80, resulting in a price-to-book (P/B) ratio of 2.72. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

20 analysts cover CRL with 25% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $156.14 implies -11.7% downside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:1 Strong Buy, 4 Buy, 14 Hold, 1 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.